RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative,…
By N. Robert, V. Diéras, J. Glaspy, A. Brufsky, I. Bondarenko, O. Lipatov, E. Perez, D. Yardley, S. Chan, Xian Zhou and 2 more. Journal of Clinical Oncology, 2011
1,047 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/f2f25791487b3f87242a0fa727ddeece13c60d97
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
Citations in the corpus
- Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. (2012, background): “Three trials have evaluated its use in advanced HER2 negative disease: Phase III E2100,51 AVADO86 and RIBBON-1.”
- An overview of triple-negative breast cancer (2016, background): “VEGF inhibitors block the growth of tumor neovasculature and the anti-VEGF monoclonal antibody, bevacizumab, has been shown to increase response rate (RR) and progression-free survival (PFS) of patients with metastatic breast cancer when added to firstline chemotherapy in various randomized phase II”
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) (2014, result): “Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, neutral): “Metastatic 1st line Paclitaxel ± bevacizumab E2100 [40] Improvement in PFS not OS Docetaxel ± bevacizumab (HER-2 negative population) AVADO [41] Improvement in PFS, OS NA Capecitabine, taxane or anthracycline ± bevacizumab (HER-2 negative population) RIBBON-1 [42] Improvement in PFS but not in OS Do”